Effects of recombinant human PLD2 on proliferation and apoptosis of HL-60 cells

Authors

  • Ling Zhu,

    Corresponding author
    1. Immunology Department and Center of Neuroscience, Fujian Medical University, No. 88 Jiaotong Road, Fuzhou, Fujian 350004, China
      Corresponding author. Tel.: +86 0591 83569048. zhling62@pub6.fz.fj.cn
    Search for more papers by this author
  • Ya-Xiong Wang,

    1. Immunology Department and Center of Neuroscience, Fujian Medical University, No. 88 Jiaotong Road, Fuzhou, Fujian 350004, China
    Search for more papers by this author
  • Chuan-Xing Yu

    1. Internal Medicine of Second People's Hospital of Fujian Province, Fuzhou, Fujian 350003, China
    Search for more papers by this author

Corresponding author. Tel.: +86 0591 83569048. zhling62@pub6.fz.fj.cn

Abstract

In the present study, we investigated the role of recombinant human phospholipase D2 (rhPLD2) on proliferation and apoptosis in human leukemia HL-60 cells which induced by camptothecin. Our research demonstrated that various concentrations of rhPLD2 inhibit the growth of HL-60 cells in a dose-dependent manner, and rhPLD2 plus camptothecin can produce a synergistic effect on growth inhibition of HL-60 cells in vitro. So, we conclude that rhPLD2 alone cannot induce apoptosis in HL-60 cells, but it can potentiate the apoptosis of HL-60 cells induced by camptothecin. Similarly, we show that both rhPLD2 and standard PLD were able to enhance camptothecin-induced apoptosis of HL-60 cells.

Ancillary